Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 8/20 | 0.82 |
| ▸ | THRA | P10827 | 7/20 | 0.82 |
| ▸ | TGM2 | P21980 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29175026 | 0.92 | THRB (0.97) | THRBTHRATGM2MEN1KMT2A | |
| SCHEMBL19854529 | 0.90 | THRB (1.00) | THRBTHRAMEN1KMT2ASPHK1 | |
| SCHEMBL9864844 | 0.90 | THRB (1.00) | THRBTHRAMEN1KMT2ASPHK1 | |
| SCHEMBL2728759 | 0.90 | THRB (1.00) | THRBTHRAMEN1KMT2ASPHK1 | |
| SCHEMBL2727638 | 0.90 | THRB (1.00) | THRBTHRAMEN1KMT2ASPHK1 | |
| SCHEMBL2729131 | 0.90 | THRB (1.00) | THRBTHRAMEN1KMT2ASPHK1 | |
| SCHEMBL19855850 | 0.88 | THRB (0.89) | THRBTHRATGM2MEN1KMT2A | |
| SCHEMBL6677167 | 0.87 | THRA (0.88) | THRBTHRATGM2MEN1KMT2A | |
| SCHEMBL20469621 | 0.85 | TGM2 (0.68) | THRBTHRATGM2ALDH1A1POLB | |
| SCHEMBL15756377 | 0.83 | THRA (0.85) | THRBTHRAMEN1KMT2ASPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062696-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-27 | — | — | US | disclosed |
| WO-2018144870-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062696-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | RTN4, RTN3, RCN1 | THRB 3748/4885THRA 3657/4885TGM2 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.